FindTrial
Sign In

Use of fibroscan as a safe diagnostic tool for diabetic pregnant women for early diagnosis of liver disease

Assessment of liver stiffness by fibroscan in pregnant women of first or second trimester with pre gestational/ gestational diabetes mellitus without known hepatic pathology for early diagnosis of liver disorders - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/04/107675
Enrollment
98
Registered
2026-04-07
Start date
Unknown
Completion date
Unknown
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O098- Supervision of other high risk pregnancies

Interventions

Intervention1: Nil: Nil

Sponsors

Indian Institute of Medical Research
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All pregnant women in first or second trimester with pre gestational or gestational diabetes mellitus without any known hepatic pathology

Exclusion criteria

Exclusion criteria: All pregnant women with known hepatic pathology

Design outcomes

Primary

MeasureTime frame
Early detection of liver disorders in pregnant women with diabetesTimepoint: Fibroscan once before delivery, preganancy outcome after delivery—

Secondary

MeasureTime frame
Better pregnancy outcomes and low risk to foetus and motherTimepoint:—

Countries

India

Contacts

Public ContactAadrita Bishnu

Aadrita Bishnu

aadrita280505@gmail.com7002801460

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: May 1, 2026